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Abstract
Background: Posttranslational modification of chemokines is one of the mechanisms that regulate leukocyte migration
during inflammation. Multiple natural NH2-terminally truncated forms of the major human neutrophil attractant interleukin-
8 or CXCL8 have been identified. Although differential activity was reported for some CXCL8 forms, no biological data are
available for others.
Methodology/Principal Findings: Aminopeptidase-cleaved CXCL8(2-77) and CXCL8(3-77), the product of alternative
cleavage of the signal peptide CXCL8(-2-77) and the previously studied forms containing 77 and 72 amino acids, CXCL8(1-
77) and CXCL8(6-77), were prepared by solid-phase peptide synthesis, purified and folded into active proteins. No
differences in binding and calcium signaling potency were detected between CXCL8(1-77), CXCL8(-2-77), CXCL8(2-77) and
CXCL8(3-77) on cells transfected with one of the human CXCL8 receptors, i.e. CXCR1 and CXCR2. However, CXCL8(-2-77) was
more potent compared to CXCL8(1-77), CXCL8(2-77) and CXCL8(3-77) in signaling and in vitro chemotaxis of peripheral
blood-derived human neutrophils. Moreover, CXCL8(-2-77) was less efficiently processed by plasmin into the more potent
CXCL8(6-77). The truncated forms CXCL8(2-77) and CXCL8(3-77) had higher affinity for heparin than CXCL8(1-77), a property
important for the presentation of CXCL8 on endothelial layers. Upon intraperitoneal injection in mice, elongated, truncated
and intact CXCL8 were equally potent to recruit neutrophils to the peritoneal cavity.
Conclusions: In terms of their ability to induce neutrophil recruitment in vivo, the multiple CXCL8 forms may be divided in
three groups. The first group includes CXCL8 proteins consisting of 75 to 79 amino acids, cleaved by aminopeptidases, with
intermediate activity on neutrophils. The second group, generated through proteolytic cleavage (e.g. by Ser proteases),
contains 69 to 72 amino acid forms which are highly potent neutrophil attractants in vivo. A third category is generated
through the modification of the arginine in the NH2-terminal region into citrulline by peptidylarginine deiminases and has
weak potency to induce neutrophil extravasation.
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Introduction
During infection, neutrophilic granulocytes are often the first
immune cells to invade the inflammatory site. In addition to
bacterial formyl peptides, complement fragment C5a and the lipid
leukotriene B4, a number of chemokines with a conserved Glu-
Leu-Arg (ELR) motif in front of the first cysteine (ELR+CXC
chemokines) attract neutrophils [1,2,3]. All human ELR+CXC
chemokines, i.e. CXCL1, CXCL2, CXCL3, CXCL5, CXCL6,
CXCL7 and CXCL8 attract and activate neutrophils through the
specific G protein-coupled CXC chemokine receptor CXCR2. In
addition, CXCL6 and CXCL8 [or interleukin (IL)-8] also interact
with CXCR1 [4]. Upon stimulation with bacterial or viral agents
or inflammatory cytokines such as IL-1b or tumor-necrosis factor-
a (TNF-a) CXCL8 can be produced by virtually any cell type
including leukocytes, fibroblasts and epithelial and endothelial cells
[5]. CXCL8 is one of the most abundant, if not the most
abundant, ELR+CXC chemokines with the highest specific
biological activity on neutrophils. CXCL8 may be transported
across endothelial layers by the Duffy antigen receptor for
chemokines (DARC) and presented to neutrophils in the blood
flow on top of the glycocalyx through its interaction with
glycosaminoglycans [1,6].
To eradicate microbial infection, neutrophils use a number of
innate immune mechanisms such as phagocytosis of bacteria and
production of intracellular reactive oxygen components and
hydrolyzing enzymes such as proteases that may be released in
the extracellular milieu upon activation [7]. Recently, the
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formation of neutrophil extracellular traps (NETs), a mechanism
that allows neutrophils to retain antimicrobial activity after death,
has been identified as an additional mechanism and alternative for
death by necrosis or apoptosis [8,9]. A side effect of these efficient
antimicrobial mechanisms and release of highly active molecules
and hydrolyzing enzymes is partial tissue destruction. To provide
the rapid and adequate immune response that is restricted in time
to the duration of the infection and to avoid chronic inflammation,
precise control of local neutrophil accumulation and activation is
essential. One of the mechanisms that regulate neutrophil
recruitment and activation is enzyme-induced posttranslational
modification of ELR+CXC chemokines [10]. In fact, the
ELR+CXC chemokine CXCL7 only becomes activated upon
proteolytic removal of a large part of the NH2-terminal region
[11,12,13]. For other ELR+CXC chemokines the activity has been
reported to be up-regulated upon limited truncation of the NH2-
terminus by specific enzymes such as plasmin, thrombin, matrix
metalloproteases, etc. [10]. However, further truncation within the
ELR motif results in almost complete inactivation of all
ELR+CXC chemokines. Numerous posttranslationally modified
natural forms of the different ELR+CXC chemokines have been
identified and partially characterized [10]. Leukocyte-derived
conditioned medium contains at least 10 different truncated and
also citrullinated forms of the most potent human ELR+CXC
chemokine, CXCL8 [14]. Incubation of CXCL8 with the myeloid
aminopeptidase CD13 results in the removal of one or two amino
acids from the 77 amino acid CXCL8(1-77) [15]. The Arg in
position 5 is a crucial amino acid for cleavage of CXCL8 into
CXCL8(6-77) by the serine proteases plasmin and thrombin.
CXCL8 truncated by five to eight NH2-terminal residues,
becomes a three- to ten-fold more potent neutrophil attractant
and angiogenic molecule in vitro and in vivo [14,16,17]. Citrullina-
tion of natural CXCL8 by peptidylarginine deiminase (PAD)-2 or
PAD-4 also occurs specifically on Arg in position 5 [14].
Citrullination significantly reduces the capacity of CXCL8 to
induce neutrophil extravasation without affecting its angiogenic
activity. However, intravenously injected citrullinated CXCL8 is a
more potent mobilizer of mature neutrophils to the blood stream
[18]. In addition to proteolytic truncation and citrullination,
alternative cleavage of the signal peptide results in a natural
CXCL8 form with two extra NH2-terminal amino acids, i.e.
CXCL8 containing 79 amino acids or CXCL8(-2-77)
[11,14,19,20,21].
Significant amounts of natural elongated CXCL8(-2-77) and
truncated CXCL8(2-77) and CXCL8(3-77) have been reported to
be produced by lymphocytes, monocytes and fibroblasts
[11,14,19,20,21]. Since these forms co-elute on chromatographic
columns with other CXCL8 forms the individual forms were not
readily available as pure proteins for the evaluation of their
biological activity. Here we produced the different CXCL8 forms
by Fmoc solid phase peptide synthesis. The biological activity of
three CXCL8 forms for which the activity was not investigated
before, i.e. CXCL8(-2-77), CXCL8(2-77) and CXCL8(3-77), was
compared with that of the previously studied CXCL8(1-77) and
the more potent CXCL8(6-77) form in receptor binding, signaling
and neutrophil migration assays.
Results
1. Chemical synthesis of the naturally occurring CXCL8
variants
Separation of the natural CXCL8 variants CXCL8(-2-77),
CXCL8(1-77), CXCL8(2-77), CXCL8(3-77) and CXCL8(6-77)
via chromatography to study their biological activity was not
feasible. These variants co-elute from analytical ion exchange and
reversed-phase high performance liquid chromatography (RP-
HPLC) columns [14,20]. Therefore, the individual proteins were
prepared by solid phase peptide synthesis, deprotected, folded and
purified to homogeneity. The accuracy of the relative molecular
mass (Mr) of the synthesized proteins was verified by electrospray-
ion trap mass spectrometry as shown in Table 1. Edman
degradation-based NH2-terminal amino acid sequencing con-
firmed the NH2-terminal protein sequence of the synthesized
chemokines (data not shown).
2. Chemokine receptor-dependent activities of truncated
CXCL8 variants
CXCL8 is a potent neutrophil-activating and -attracting
chemokine, binding to CXCR1 and CXCR2. Following activation
of one of these receptors, a rapid increase in the intracellular
calcium concentration ([Ca2+]i) is elicited, a process crucial for the
induction of several cellular responses (related and unrelated to
neutrophil migration). The calcium signaling potencies of the
truncated CXCL8 variants were compared with intact CXCL8(1-
77) (Figure 1A, 1B, 1C). The effects of truncation on the signaling
activity of CXCL8 were similar on CXCR1-transfected HEK293
cells, CXCR2-transfected HEK293 cells and freshly isolated human
blood neutrophils. As expected, CXCL8(6-77) was a three- to ten-
fold more potent agonist of CXCR1 and CXCR2 than CXCL8(1-
77). In contrast, more limited NH2-terminal truncation, generating
CXCL8(2-77) or CXCL8(3-77), did not influence the signaling
potency of CXCL8. The dose-response curves of CXCL8(1-77),
CXCL8(2-77) and CXCL8(3-77) coincided in CXCR1-transfected
cells, CXCR2-transfected cells and neutrophils, the minimal
effective concentration inducing an increase in [Ca2+]i being
1 nM and 3 nM on CXCR1- and CXCR2-transfected HEK293
cells, respectively. Calcium responses in fresh human neutrophils
were already detectable upon stimulation with 0.3 nM CXCL8(1-
77), CXCL8(2-77) and CXCL8(3-77).
Analogous results were obtained when comparing the in vitro
neutrophil chemotactic activity of these CXCL8 variants (Figure 1D),
yielding similar bell-shaped dose-response curves for CXCL8(1-77),
CXCL8(2-77) and CXCL8(3-77). The efficacy (the maximal
chemotactic response) of CXCL8(6-77) was higher than that of
CXCL8(1-77) (chemotactic index 4.75 vs. 3.76) and was reached at
three-fold lower CXCL8 concentrations (1 vs. 3 nM). Remarkably,
CXCL8(3-77) was more efficacious compared to CXCL8(1-77). It
reached a significantly higher chemotactic index at the concentration
resulting in the optimal chemotactic response (3 nM).
3. Chemokine receptor-dependent activity of the
elongated CXCL8 variant
The calcium signaling potency of CXCL8(1-77) was also
compared with that of the elongated isoform of CXCL8, i.e.
CXCL8(-2-77). As shown in Figure 2 (panel A, B and C), signaling
through CXCR1 or CXCR2 was comparable for CXCL8(1-77)
and CXCL8(-2-77). However, on neutrophils CXCL8(-2-77)
appeared to be a slightly more potent inducer of calcium
mobilization. Indeed, 1 nM CXCL8(-2-77) induced a significantly
higher increase in [Ca2+]i compared to 1 nM CXCL8(1-77). In
addition, for CXCL8(-2-77) a three-fold lower concentration was
required in vitro to induce a comparable response in neutrophil
chemotaxis assays compared to CXCL8(1-77) (Figure 2D).
4. Binding properties of the CXCL8 variants
To evaluate the binding efficiency of the different CXCL8
isoforms to the G protein-coupled receptors CXCR1 and
Activity of Elongated and Truncated CXCL8
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CXCR2, their ability to compete for 125I-labeled CXCL8(6-77)
binding to these receptors was compared (Figure 3A and 3B).
CXCL8(1-77) competed with radiolabeled CXCL8 in a dose-
dependent manner for binding to both CXCR1 and CXCR2. The
NH2-terminal variants CXCL8(2-77), CXCL8(3-77) and
CXCL8(-2-77) were as potent as CXCL8(1-77) in displacing
radiolabeled CXCL8 from either CXCR1 or CXCR2. In contrast
to these isoforms, but confirming previously published results [14],
CXCL8(6-77) displayed increased binding affinity for both
CXCR1 and CXCR2 as it displaced radiolabeled CXCL8 about
Table 1. Chemical synthesis of naturally occurring CXCL8 variants.
CXCL8 forma NH2-terminal amino acid sequence Mr (theoretical)
Experimentally determined Mr of
synthetic CXCL8
CXCL8(-2-77) -2EGAVLPRSAK ELR CQC 9104.7 9106.7
CXCL8(1-77) 1AVLPRSAK ELR CQC 8918.5 8918.8
CXCL8(2-77) 2VLPRSAK ELR CQC 8847.4 8847.6
CXCL8(3-77) 3LPRSAK ELR CQC 8748.3 8748.6
CXCL8(6-77) 6SAK ELR CQC 8381.8 8381.9
aCXCL8(-2-77), CXCL8(1-77), CXCL8(2-77), CXCL8(3-77) and CXCL8(6-77) were chemically synthesized as described in the Materials & Methods section. After purification,
the Mr of the proteins was checked by electrospray ion trap mass spectrometry and the NH2-terminal amino acid sequence was confirmed by NH2-terminal sequencing
based on Edman degradation.
doi:10.1371/journal.pone.0023913.t001
Figure 1. Chemokine receptor-dependent activity of the truncated CXCL8 isoforms in vitro. Intracellular calcium signaling upon activation
of CXCR1 or CXCR2 was measured in HEK293 cells transfected with CXCR1 (panel A) or CXCR2 (panel B) or in neutrophilic granulocytes (panel C).
Increases in the [Ca2+]i (6 SEM) are shown upon stimulation of the cells with the indicated concentrations of CXCL8(1-77) (¤), CXCL8(2-77) (&),
CXCL8(3-77) (m) or CXCL8(6-77) (N). The dashed line indicates the detection limit (an increase in [Ca2+]i of 20 nM). The Mann-Whitney U test was used
to detect statistical differences [*, p,0.05; **, p,0.01; compared to the corresponding concentration of CXCL8(1-77)] (n$3). The neutrophil
chemotactic activity of CXCL8(1-77) (¤), CXCL8(2-77) (&), CXCL8(3-77) (m) and CXCL8(6-77) (N) was evaluated in 96-well Boyden chambers (panel D).
Values represent the mean chemotactic index (6 SEM). Statistical analysis was performed using the Mann-Whitney U test [*, p,0.05; **, p,0.01;
compared to the corresponding concentration of CXCL8(1-77)] (n = 6).
doi:10.1371/journal.pone.0023913.g001
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3-fold more efficiently. Remarkably, on CXCR1-transfected cells
and at low concentrations, CXCL8(2-77), CXCL(3-77) and
CXCL8(-2-77) seem to be more potent competitors compared to
CXCL8(1-77). However, this difference is significant at 3 nM
only.
Glycosaminoglycan binding is indispensable for chemokines in
order to build up a chemotactic gradient in vivo and to be presented
on the endothelial glycocalyx. The heparin binding affinity of the
CXCL8 variants was compared in an enzyme-linked immunosor-
bent saturation binding assay (Figure 3). The previously reported
equal heparin binding affinity of CXCL8(1-77) and CXCL8(6-77)
was confirmed [14]. Furthermore, this assay showed that the
truncated CXCL8 variants CXCL8(2-77) and CXCL8(3-77)
displayed about three-fold higher binding affinities for heparin
than CXCL8(1-77). Despite the presence of an extra negatively
charged acidic NH2-terminal amino acid (i.e. Glu), the heparin
binding efficiency of CXCL8(-2-77) was moderately higher than
the binding efficiency of CXCL8(1-77).
5. Susceptibility of CXCL8 forms to cleavage by thrombin
and plasmin
The plasma serine proteases plasmin and thrombin cleave
CXCL8(1-77) in a very efficient way, thereby potentiating its
neutrophil chemotactic activity [22,23]. Plasmin has a preference
for the peptide bond between Arg5 and Ser6, although minor
cleavage of the Lys8-Glu9 bond also occurs, whereas thrombin
specifically cleaves the Arg5-Ser6 bond of CXCL8. To study
whether NH2-terminal truncation by one or two amino acids or
the additional Glu-Gly dipeptide hinder or promote plasmin- or
thrombin-mediated cleavage, processing of CXCL8(1-77),
CXCL8(2-77), CXCL8(3-77) and CXCL8(-2-77) by these prote-
ases was analyzed by mass spectrometry. All four substrates were
converted with comparable efficiency by thrombin (data not
shown), showing that limited variation of the length of the CXCL8
NH2-terminus did not affect the cleavage rate of thrombin.
Similarly, the susceptibility of CXCL8 for cleavage by plasmin was
not changed by limited NH2-terminal truncation. In contrast,
plasmin cleaved CXCL8(-2-77) less efficiently compared to
CXCL8(1-77) (Figure 4). Under the experimental conditions
described in the Materials & Methods section, approximately 41%
of CXCL8(-2-77) versus 79% of CXCL8(1-77) had undergone
proteolysis by plasmin after 30 min of incubation. Complete
conversion of CXCL8(1-77) was achieved upon 60 min of
incubation, whereas at that moment more than 40% of
CXCL8(-2-77) was still intact. This difference in susceptibility
may influence the biological activity of CXCL8(-2-77) in vivo.
6. Neutrophil migration in vivo induced by CXCL8 forms
The in vivo neutrophil recruitment potency of the NH2-terminal
CXCL8 variants was compared with that of CXCL8(1-77).
Although no homologous murine CXCL8 equivalent exists,
human CXCL8 activates murine neutrophils. Mice were intra-
peritoneally (i.p.) injected with the CXCL8 forms and after 2 h the
peritoneal cavity was washed and the number of leukocytes and
Figure 2. Chemokine receptor-dependent activity of the elongated CXCL8 variant in vitro. Intracellular calcium signaling upon activation
of CXCR1 or CXCR2 was measured in HEK293 cells transfected with CXCR1 (panel A) or CXCR2 (panel B) or in neutrophilic granulocytes (panel C).
Increases of the [Ca2+]i (6 SEM) are shown upon stimulation of the cells with the indicated concentrations of CXCL8(1-77) (¤) or CXCL8(-2-77) (#).
The dashed line indicates the detection limit (an increase in [Ca2+]i of 20 nM). The Mann-Whitney U test was used to detect statistical differences
[*, p,0.05; compared to the corresponding concentration of CXCL8(1-77)] (n$3). The neutrophil chemotactic activity of CXCL8(1-77) (¤) or CXCL8(-2-
77) (#) was evaluated in 96-well Boyden chambers (panel D). Values represent the mean chemotactic index (6 SEM). Statistical analysis was
performed using the Mann-Whitney U test [*, p,0.05; compared to the corresponding concentration of CXCL8(1-77)] (n = 6).
doi:10.1371/journal.pone.0023913.g002
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the percentage of neutrophils were determined. In this in vivo
model, the neutrophil influx induced by CXCL8(1-77), CXCL8(2-
77), CXCL8(3-77) and CXCL8(-2-77) was comparable (Figure 5).
Indeed, injection (i.p.) of 100 pmol of either of these isoforms
elevated the number of neutrophils in the peritoneal cavity from
about 2.104 neutrophils/ml (upon vehicle injection) to approxi-
mately 30.104 neutrophils/ml. As a positive control, CXCL8(6-77)
was included in this assay. The higher potency of CXCL8(6-77)
compared to CXCL8(1-77) could be confirmed, as the median
number of neutrophils present in the intraperitoneal lavage upon
injection of 100 pmol of CXCL8(6-77) is significantly higher than
upon injection of 100 pmol of CXCL8(1-77) (70.104 neutrophils/
ml vs. 30.104 neutrophils/ml). Thus, no difference in neutrophil
recruitment potency was detected between CXCL8(1-77),
CXCL8(2-77), CXCL8(3-77) and CXCL8(-2-77) in this in vivo
assay in mice, despite the small, but significant differences
observed in calcium mobilization, chemotaxis and heparin binding
assays and regarding the sensitivity to proteolytic activation by
plasmin (vide supra).
Discussion
IL-8 or CXCL8 is the most potent human chemokine with
neutrophil chemotactic properties. Already upon the initial
isolation of natural human CXCL8 it was clear that several
different NH2-terminal isoforms of CXCL8 are produced by
leukocytes or fibroblasts under inflammatory conditions
[11,19,20,21,22]. Posttranslational modifications can alter the
biological activity (receptor affinity and signaling potency),
interaction with other molecules (e.g. glycosaminoglycans),
clearance of chemokines and hence the in vivo inflammatory
properties [10]. The most abundant CXCL8 isoforms CXCL8(1-
77) and CXCL8(6-77), produced by endothelial cells [24,25],
fibroblasts [19] and monocytes [21,26] respectively, have been
studied extensively. These studies revealed that the removal of five
NH2-terminal amino acids (AVLPR) potentiates the neutrophil
chemotactic activity of CXCL8 both in vitro and in vivo [14,22,23].
Additional limited NH2-terminal truncations to CXCL8(8-77) and
CXCL8(9-77) gradually increase the chemotactic potency in vitro,
Figure 3. Binding properties of the CXCL8 isoforms. HEK293 cells
transfected with CXCR1 (A) or CXCR2 (B) were incubated with increasing
concentrations of unlabeled CXCL8(-2-77) (#), CXCL8(1-77) (¤),
CXCL8(2-77) (&), CXCL8(3-77) (m) or CXCL8(6-77) (N), together with125I-labeled CXCL8(6-77). The mean remaining % of 125I-CXCL8(6-77)
binding (6 SEM) is specified at the y-axis [n$4 (1 to 300 nM); n = 2
(0,3 nM)]. Analysis of the interaction of the CXCL8 variants with heparin
was performed using heparin binding plates. The indicated concentra-
tions of CXCL8(-2-77) (#), CXCL8(1-77) (¤), CXCL8(2-77) (&), CXCL8(3-
77) (m) and CXCL8(6-77) (N) were added to immobilized heparin, the
binding equilibrium was achieved and bound CXCL8 was detected with
labeled antibodies. The mean (from four to six independent exper-
iments) percentage heparin binding [compared to 300 nM CXCL8(1-77)]
(6 SEM) for the individual CXCL8 forms is indicated at the y-axis. To
detect statistically significant differences between the CXCL8 variants
and CXCL8(1-77), the Mann-Whitney U test was carried out [$,*,#,1,
p,0.05; **,##,11, p,0.01; for comparison of CXCL8(-2-77) ($),
CXCL8(2-77) (*), CXCL8(3-77) (#) and CXCL8(6-77) (1) with CXCL8(1-77)].
doi:10.1371/journal.pone.0023913.g003
Figure 4. Susceptibility of CXCL8(-2-77) to proteolysis by
plasmin. CXCL8(1-77) and CXCL8(-2-77) were incubated with plasmin
and the degree of conversion was determined using electrospray ion
trap mass spectrometry. Percentages of intact CXCL8 [either CXCL8(1-
77) or CXCL8(-2-77)] (black histograms), CXCL8(6-77) (dark grey
histograms) and CXCL8(9-77) (light grey histograms) generated upon
incubation with plasmin are depicted in function of time (min).
doi:10.1371/journal.pone.0023913.g004
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suggesting that CXCL8(6-77) is not the most active form of
CXCL8 [16,27]. A crucial role in receptor binding and activation
has been ascribed to the ELR motif in front of the CXC sequence
using both chemically synthesized truncated and mutated analogs
[16,28]. Thus far, truncation of the NH2-terminus of CXCL8 has
been shown to result in potentiation as long as proteases do not
cleave in and beyond the ELR motif.
In this study, the elongated natural variant of CXCL8, i.e.
CXCL8(-2-77) and the truncated forms CXCL8(2-77) and
CXCL8(3-77) were characterized. The elongated form is pre-
sumed to arise from alternative cleavage of the signal peptide of
the 99 amino acid precursor [29]. It has been detected in medium
of peripheral blood mononuclear cells (PBMCs) conditioned with
lipopolysaccharide (LPS), concanavalin A or a combination of
polyriboinosinic polyribocytidylic acid (PIC) and interferon-c,
where it constitutes about 8 to 10% of the total amount of CXCL8
produced [11,14,20,21]. In addition, the supernatant of cultured
IL-1a- or TNF-a-stimulated dermal fibroblasts contains significant
amounts of CXCL8(-2-77) [19]. Albeit less abundant, the
truncated forms CXCL8(2-77) and CXCL8(3-77) have also been
isolated from the conditioned medium of PBMCs [14]. These
forms may result from aminopeptidase (e.g. CD13)-mediated
cleavage of secreted CXCL8(1-77) [15].
The results presented here show that the NH2-terminally
different isoforms described do not differ a lot in their effects on
binding to and signaling through CXCR1 or CXCR2. The
receptor binding and calcium signaling potency of CXCL8(1-77),
CXCL8(2-77), CXCL8(3-77) and CXCL8(-2-77) is similar in both
CXCR1- or CXCR2-transfected cells. However, in calcium
signaling and in vitro chemotaxis assays on freshly isolated blood
neutrophils, expressing both CXCR1 and CXCR2, stronger
responses to stimulation with CXCL8(-2-77) than towards stimu-
lation with CXCL8(1-77) were observed. Moreover, small alter-
ations in the NH2-terminal region do influence the GAG binding
affinity of CXCL8. CXCL8(2-77) and CXCL8(3-77) displayed a
three-fold higher affinity for heparin compared to CXCL8(1-77).
Although not as explicit as the truncated isoforms, CXCL8(-2-77)
also bound heparin with higher affinity than CXCL8(1-77).
Conversion of CXCL8 into the more potent neutrophil chemoat-
tractant CXCL8(6-77) by the serine proteases plasmin and
thrombin was not affected by prior removal of the NH2-terminal
amino acids Ala1 or Val2. This is in contrast to CXCL8
citrullination which prevented subsequent CXCL8 activation by
these serine proteases [14]. On the other hand, CXCL8(-2-77),
generated through alternative cleavage of the signal peptide, was
less susceptible to cleavage by plasmin. Finally, the neutrophil-
attracting activity of CXCL8(-2-77), CXCL8(1-77), CXCL8(2-77)
and CXCL8(3-77) were evaluated in vivo upon i.p. injection in mice.
During in vivo leukocyte migration, many more parameters come
into play, including glycosaminoglycan binding and alteration of the
expression pattern of adhesion molecules such as selectins and
integrins. Despite the slightly increased in vitro chemotactic potency
and GAG binding affinity, the in vivo neutrophil-attracting potency
of CXCL8(-2-77) upon i.p. injection in mice did not differ from that
of CXCL8(1-77). Injection of 100 pmol of CXCL8(1-77) or
100 pmol of CXCL8(-2-77) both elevated the percentage of
neutrophils in the peritoneal cavity from about 2% to 18%.
Perhaps, the higher variability of in vivo assays prohibits detection of
small differences in biological activity. Alternatively, the reduced
susceptibility of CXCL8(-2-77) to cleavage and activation by
plasmin may counteract the increased chemotactic potency and
GAG binding property of CXCL8(-2-77). Although alternative
cleavage of the signal peptide of the CXCL8 precursor was reported
in various publications, it does not seem to have an effect on the in
vivo neutrophil-attracting activity of CXCL8 and thus, does not
constitute a major regulatory mechanism. Furthermore, although
NH2-terminal removal of amino acids one by one from CXCL8(6-
77) was reported to improve the activity in vitro [16], aminopeptidase
treatment of CXCL8(1-77) resulting in the generation of CXCL8(2-
77) and CXCL8(3-77) did not progressively generate more potent
isoforms in vivo compared to CXCL8(1-77).
Figure 5. Neutrophil-attracting activity of the CXCL8 isoforms
in vivo. The neutrophil influx upon i.p. injection of the specified doses
of the CXCL8 isoforms in mice was investigated. 2 hours post-injection,
the peritoneal cavity was washed and the overall number of leukocytes
determined. Differential microscopic counting of Hemacolor-stained
cells allowed to define the percentage of neutrophils (panel A) and the
total number of neutrophils (panel B) present in the peritoneal cavity.
Squares show the median neutrophil influx (formulated as percentages
or total counts/ml); the bottom and the top of the rectangle denote the
25th and 75th percentile; whiskers represent the non-outlier range
(coefficient 1.5). Outliers are plotted as circles. Control mice (co) were
treated with vehicle and illustrate the spontaneous migration of
neutrophils to the peritoneal cavity. The Mann-Whitney U test was used
for statistical analysis [1, p,0.01; compared with 100 pmol CXCL8(1-
77)]. The numbers depicted in (or besides) the rectangular box
represent the number of mice treated.
doi:10.1371/journal.pone.0023913.g005
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Combining these results with the results previously described for
CXCL8(6-77) and [Cit5]CXCL8(1-77) [14], we can conclude that,
based on their potency to recruit neutrophils, the NH2-terminal
variants of CXCL8 can be divided into 3 subgroups (Figure 6). A
first group contains CXCL8(-2-77), CXCL8(1-77), CXCL8(2-77)
and CXCL8(3-77), which display intermediate neutrophil-attract-
ing capacity. Upon removal of 5 to 8 NH2-terminal amino acids,
CXCL8 more efficiently attracts neutrophils, therefore these
isoforms [i.e. CXCL8(6-77), CXCL8(7-77), CXCL8(8-77) and
CXCL8(9-77)] form a second group with enhanced biological
activity. Citrullinated CXCL8 belongs to a third category as it
displays no or low neutrophil-attracting potency. The significant
differences in terms of their ability to recruit neutrophils, point
towards the importance of differential detection of these individual
isoforms in patient samples and towards a potentially important
role for CXCL8-modifying enzymes such as plasmin, thrombin
and PADs in fine-tuning neutrophil migration under pathological
conditions. Quantification of the individual CXCL8 forms in
patient samples will help to unveil the potential pathophysiological
role of these different CXCL8 isoforms.
Materials and Methods
Ethics statement
The experimental protocols (involving the use of laboratory
animals) were carried out in strict accordance with the Belgian and
European guidelines concerning the handling of laboratory
animals and were approved by the Animal Ethical Committee of
the K.U.Leuven (approved project P07029).
No specific approval from an institutional review board is
required for the use of buffy coats for the following reasons: (1) no
personal patient information is made available, (2) buffy coats
cannot be used for treatment of patients and are waste products for
the blood transfusion centre and (3) blood donors sign an
agreement that parts of the donation that cannot be used for
patient treatment may be used for scientific research.
Reagents and cells
Recombinant human CXCL8(1-77) and CXCL8(6-77) were
obtained from PeproTech (Rocky Hill, NJ, USA). Thrombin and
plasmin purified from human plasma were purchased from Sigma-
Aldrich (St. Louis, MO, USA). Human embryonic kidney (HEK)
293 cells transfected with human CXCR1 or CXCR2 were
provided by Dr. J. M. Wang (National Cancer Institute, Frederick,
MD) [30] and cultured in Dulbecco’s modified Eagle’s medium
(DMEM; Lonza, Basel, Switzerland) supplemented with 10% (v/v)
fetal bovine serum (FBS) and 800 mg/ml geneticin (Invitrogen,
Merelbeke, Belgium).
Enzymatic modification of CXCL8 in vitro
To evaluate the susceptibility of CXCL8 variants to enzymatic
modification by plasmin or thrombin, human CXCL8 variants
were incubated with thrombin or plasmin at 37uC for the
indicated time intervals at enzyme-substrate (E/S) molar ratios of
1/100 and 1/1000, respectively. Cleavage was accomplished in
phosphate-buffered saline (PBS) (pH 7.4). CXCL8 processing was
stopped by adding 0.1% (v/v) trifluoroacetic acid (TFA). Processed
preparations were desalted on C4 ZipTips (Millipore, Billerica,
MA, USA) and analyzed by electrospray ion trap mass
spectrometry (Esquire LC ion trap mass spectrometer; Bruker,
Bremen, Germany).
Chemical synthesis of CXCL8 and the posttranslationally
modified isoforms
CXCL8(-2-77), CXCL8(1-77), CXCL8(2-77), CXCL5(3-77)
and CXCL8(6-77) were chemically synthesized based on
fluorenyl methoxycarbonyl (Fmoc) chemistry using a 433A solid
phase peptide synthesizer (Applied Biosystems, Foster City, CA,
USA), as described by Loos et al. [31]. Intact synthetic peptides
were separated from incompletely synthesized by-products by
RP-HPLC on a Source 5-RPC column (4.66150 mm; GE
Healthcare Bio-sciences, Little Chalfont, United Kingdom)
applying an acetonitrile gradient in 0.1% (v/v) TFA. Part
(0.7%) of the column effluent was split online to an ion trap mass
spectrometer (Esquire LC). Fractions containing the protein with
the correct Mr were folded overnight, subsequently loaded on a
C8 RP-HPLC column (Aquapore-RP 300 2.16220 mm; Perki-
nElmer, Waltham, MA, USA) and eluted with an acetonitrile
gradient in 0.1% TFA. Proteins eluting from the column were
detected spectrophotometrically at 214 nm and the Mr was
measured online by ion trap mass spectrometry. Homogenous
CXCL8 fractions were pooled, lyophilized and dissolved in
ultrapure water (MilliQ; Millipore). Several assays were applied
to determine protein concentrations, i.e. enzyme-linked immu-
nosorbent assay (ELISA), NH2-terminal sequencing based on
Edman degradation (491 cLC protein sequencer, Applied
Biosystems), sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis (SDS-PAGE) and bicinchoninic acid (BCA) protein assay
(Pierce, Rockford, IL, USA).
Figure 6. Overview of the naturally occurring CXCL8 isoforms.
Several NH2-terminally modified isoforms of CXCL8 have been purified
from the conditioned medium of leukocytes, fibroblasts and endothelial
cells. The NH2-terminal and COOH-terminal sequences of these isoforms
are depicted in the one-letter code (B = citrulline). Based on the criteria
formulated by Von Heijne [29], the 99 amino acid precursor molecule
may be cleaved by signal peptidases between Cys20 and Glu21 or
between Gly22 and Ala23, the latter being more probable. Indeed both
resulting CXCL8 proteins have been identified and are indicated in this
manuscript as CXCL8(-2-77) and CXCL8(1-77), respectively. CXCL8(1-77)
can be cleaved by a number of proteases, resulting in the listed NH2-
terminally truncated forms. Furthermore, CXCL8 can be citrullinated by
peptidylarginine deiminase (PAD). These NH2-terminal modifications
differently affect the ability of CXCL8 to recruit neutrophils. The in vivo
neutrophil-attracting activity is defined in the boxes at the right.
CXCL8(-2-77), CXCL8(1-77), CXCL8(2-77) and CXCL8(3-77) show compa-
rable intermediate activity. The more extensively truncated isoforms
CXCL8(6-77), CXCL8(7-77), CXCL(8-77) and CXCL8(9-77), in contrast,
display enhanced neutrophil recruiting potency, whereas citrullination
significantly lowers the capacity of CXCL8 to guide neutrophils. (MMP,
matrix metalloprotease).
doi:10.1371/journal.pone.0023913.g006
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Isolation of granulocytes from fresh human buffy coats
Fresh human buffy coats were obtained from the Blood
Transfusion Center of the Red Cross (Leuven, Belgium). The bulk
of erythrocytes were removed by sedimentation in erythrocyte-
aggregating hydroxyethyl starch (Plasmasteril, Fresenius AG, Bad
Homburg, Germany) for 30 min. After centrifugation, the leukocyte
pellet was dissolved in PBS and layered on Ficoll-sodium diatrizoate
medium (Lymphoprep, Axis-Shield PoC AS, Oslo, Norway) in
order to separate mononuclear cells from granulocytes by density
gradient centrifugation (30 min, 4006g). Residual erythrocytes in
the granulocyte pellet were eliminated by hypotonic shock (30 s) in
ultrapure water (MilliQ). Purified granulocytes were used for
chemotaxis and calcium signaling experiments.
Calcium mobilization through CXCR1 and CXCR2 by
CXCL8
The capacity of the CXCL8 isoforms to induce signaling
through human CXCR1 or human CXCR2 resulting in an
increase of the [Ca2+]i was tested on both freshly purified
granulocytes and CXCR1- and CXCR2-transfected HEK293
cells, as described [32].
Neutrophil migration in vitro and in vivo in response to
CXCL8
The chemotactic activity of the different CXCL8 isoforms for
neutrophilic granulocytes in vitro was compared using a 96-well
Boyden chamber-based chemotaxis assay (Multiscreen plates,
Millipore) and migrated neutrophils were quantified with a
luminescence ATP detection assay (PerkinElmer), as previously
described [32].
In vivo blood vessel extravasation of circulating neutrophilic
granulocytes into the peritoneal cavity was examined by i.p.
injection of endotoxin-free CXCL8 [in 0.9% (w/v) NaCl] or vehicle
in female NMRI mice (8–10 weeks, raised pathogen-free; Elevage
Janvier, Le Genest Saint Isle, France). Endotoxin concentrations
were evaluated with the Limulus amoebocyte lysate test (Cambrex,
East Rutherford, NJ, USA). After 2 h, mice were sacrificed and the
peritoneal cavity was washed with 5 ml saline enriched with 2% (v/
v) FBS and 20 U/ml heparin. Total leukocyte counts in the
peritoneal lavage were determined. 105 cells were used for the
preparation of two cytospins/mouse. After Hemacolor (Merck,
Darmstadt, Germany) staining, percentages of neutrophils in the
peritoneal lavage were determined in duplicate by differential
microscopic counting of at least 100 leukocytes per cytospin.
Binding of CXCL8 to chemokine receptors CXCR1 and
CXCR2
The binding capacity of the CXCL8 isoforms was evaluated
through the measurement of competition with 125I-labeled
CXCL8(6-77) (PerkinElmer). CXCR1- or CXCR2-transfected
cells (26106), reconstituted in binding buffer (50 mM HEPES,
1 mM CaCl2, 5 mM MgCl2 and 0.1% (w/v) bovine serum
albumin), were incubated for 2 h with radiolabeled CXCL8 and
varying concentrations of unlabeled CXCL8. Subsequently, the
cells were washed twice with 1 ml of binding buffer. Finally,
gamma radiation emitted by the cells was measured with a gamma
counter. Maximal 125I-CXCL8(6-77) binding was determined by
incubating the cells with radiolabeled CXCL8 alone and was set at
100%.
Binding of CXCL8 to heparin
The heparin binding properties of the CXCL8 isoforms were
compared on heparin binding plates (Iduron, Paterson Institute for
Cancer Research, University of Manchester, Manchester, UK),
which adsorb heparin without modification to retain the protein-
binding characteristics. Heparin (Low in calcium; Iduron), diluted
in standard assay buffer (SAB; 100 mM NaCl, 50 mM sodium
acetate, 0.2% v/v Tween-20; pH 7.2) (25 mg/ml) was coated
overnight at room temperature on the plasma-polymerized surface
of heparin binding plates. After three wash steps with SAB, the
plates were blocked with blocking buffer (SAB enriched with 0.2%
w/v gelatin) for 1 h at 37uC. Blocking buffer was discarded and
dilutions of CXCL8 (in blocking buffer) were added in triplicate
and incubated for 2 h at 37uC. Unbound CXCL8 was removed by
three washes with SAB and bound CXCL8 was detected with
biotinylated polyclonal rabbit anti-human CXCL8 (PeproTech),
diluted in blocking buffer. After 1 h of incubation at 37uC, the
plates were washed with SAB. Horse radish peroxidase-labeled
streptavidin was added for 30 min at 37uC. Subsequently, the
plates were washed and the peroxidase activity was quantified by
adding a horse radish peroxidase substrate solution and conversion
of 3,39,5,59-tetramethylbenzidine, supplemented with 0.004% (v/
v) H2O2 was measured at 450 nm using a spectrophotometer.
Equal affinity of the biotinylated anti-human CXCL8 antibody for
the different CXCL8 variants was verified. Percentage heparin
binding was calculated by subtracting the mean optical density
(OD) of the control samples (blocking buffer) from the average OD
of the test sample, followed by division by the average OD
obtained with 300 nM of CXCL8(1-77) and multiplication by 100.
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